Galanthamine, an acetylcholinesterase (AChE) inhibitor, is an Amaryllidaceae alkaloid that has emerged as a valuable therapeutic agent in the palliative management of Alzheimer’s disease (AD) symptoms following its FDA approval in 2001. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.